Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BRAIN Biotech AG's FCF Margin % or its related term are showing as below:
LTS:0RFI'
s FCF Margin % Range Over the Past 10 Years
Min: -42.04 Med: -20.81 Max: -9.7
Current: -11.63
During the past 11 years, the highest FCF Margin % of BRAIN Biotech AG was -9.70%. The lowest was -42.04%. And the median was -20.81%.
LTS:0RFI's FCF Margin % is ranked worse than 82.23% of 1576
companies
in the Chemicals industry
Industry Median: 1.95
vs LTS:0RFI: -11.63
BRAIN Biotech AG FCF Margin % Related Terms
BRAIN Biotech AG FCF Margin % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RFI vs LIN, SHW, ECL: FCF Margin % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG FCF Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (LTS:0RFI) has a FCF Margin % of 6.38% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #1296 out of 1576 companies in the Chemicals industry, placing it in the top 82.2%.
Is BRAIN Biotech AG's FCF Margin % too high?
BRAIN Biotech AG's current FCF Margin % is 6.38%. The Chemicals industry median FCF Margin % is 1.95. BRAIN Biotech AG's value of 6.38% is 227.2% above this industry median. Based on the distribution chart, BRAIN Biotech AG ranks #1296 out of 1576 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's FCF Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1296 out of 1576 companies for FCF Margin %. This places BRAIN Biotech AG in the lower half of its industry. The industry median FCF Margin % is 1.95. BRAIN Biotech AG's value of 6.38% is 227.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Chemicals company?
The median FCF Margin % among Chemicals companies is 1.95, based on 1,576 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRAIN Biotech AG's current FCF Margin % of 6.38% is 227.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median FCF Margin % is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current FCF Margin % is 6.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (LTS:0RFI) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.91 — trading 7.8% above its estimated fair value. The current FCF Margin % is 6.38% and 227.2% above the Chemicals industry median of 1.95. BRAIN Biotech AG's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BRAIN Biotech AG (LTS:0RFI), the current FCF Margin % is 6.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (LTS:0RFI) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.91 is trading 7.8% above its estimated GF Value™ of €2.70.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for LTS:0RFI:
FCF Margin %: 6.38%
GF Value™: €2.70 vs. price of €2.91 (7.8% above fair value)
Industry Position: 227.2% above the Chemicals median (#1296 of 1576)
No single metric tells the full story. See the LTS:0RFI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
60GF Score
Get the complete analysis for LTS:0RFI
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RFI has been successfully added to your 
